333. ハッチンソン・ギルフォード症候群 Hutchinson-Gilford syndrome Clinical trials / Disease details


臨床試験数 : 7 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04512963
(ClinicalTrials.gov)
August 24, 20206/8/2020Phase I Study of Progerinin in Healthy VolunteersA Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy VolunteersHutchinson-Gilford Progeria Syndrome;Werner SyndromeDrug: Progerinin;Drug: PlaceboPRG Science & Technology Co., Ltd.Amarex Clinical ResearchCompleted18 Years45 YearsAll64Phase 1United States
2NCT03895528
(ClinicalTrials.gov)
June 8, 202027/3/2019Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid LaminopathyA Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid LaminopathyProgeria;HGPSDrug: LonafarnibEiger BioPharmaceuticalsNULLApproved for marketing12 MonthsN/AAllNULL
3NCT03871972
(ClinicalTrials.gov)
March 5, 20197/3/2019Umbilical Cord Blood Transfusion in Progeria SyndromeSafety and Efficacy of Umbilical Cord Blood Transfusion in Patients With Hutchinson-Gilford Progeria SyndromeHutchinson-Gilford Progeria SyndromeDrug: Umbilical Cord Blood UnitBundang CHA HospitalNULLCompletedN/AN/AAll2Phase 1/Phase 2Korea, Republic of
4NCT00916747
(ClinicalTrials.gov)
August 20095/6/2009Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children's HospitalSchering-Plough;Merck Sharp & Dohme Corp.;Eiger BioPharmaceuticalsActive, not recruitingN/AN/AAll85Phase 2United States
5NCT00879034
(ClinicalTrials.gov)
March 20098/4/2009A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children's HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughCompletedN/AN/AAll5Phase 2United States
6NCT00731016
(ClinicalTrials.gov)
October 20081/8/2008Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidTreatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidHutchinson-Gilford Progeria SyndromeDrug: Zoledronic acid, pravastatinAssistance Publique Hopitaux De MarseilleNULLCompleted3 YearsN/ABoth15Phase 2France
7NCT00425607
(ClinicalTrials.gov)
May 200722/1/2007Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaAn Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: LonafarnibMonica E. KleinmanSchering-PloughCompleted1 YearN/AAll29Phase 2United States